[The effectiveness of platinum in mono- anc combination therapy in a prospective multicenter study].
By means of a prospective randomized trial the efficacy of DDP (DDP Lachema CSSR) alone and in combination with adriamycin (ADM Farmitalia) and cyclophosphamide (Germed) was evaluated in cases of persistent or recidivious ovarian cancers. In the study were 135 patients included. The fate of 132 patients could be evaluated. The treatment shows the following results. (Table; see text) The survival time (in average) amounts in case of CR 103 respective 108 weeks, in cases of PR 80 resp. 63 weeks. The side effects of the chemotherapy ranged between 15% (neurotoxicity) and 95% (nausea and vomiting). Regarding the hopeless situation this attempt of prolongation of life-time seems to be justified.
Krafft
W
W
Arbeitsgruppe Tumorchemotherapie in der Gynäkologie der DDR.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011446:Prospective Studies; D012086:Reoperation; D015996:Survival Rate
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin
Die Effektivität von Platin als Mono- und Kombinationstherapie bei prospektiven Multizenterstudie.